Association Between Mannose-Binding Lectin and Vascular Complications in Type 1 Diabetes

  1. Troels K. Hansen1,
  2. Lise Tarnow2,
  3. Steffen Thiel3,
  4. Rudi Steffensen4,
  5. Coen D. Stehouwer5,
  6. Casper G. Schalkwijk5,
  7. Hans-Henrik Parving26 and
  8. Allan Flyvbjerg1
  1. 1Immunoendocrine Research Unit, Medical Department M and Medical Research Laboratories, Aarhus University Hospital, Aarhus, Denmark
  2. 2Steno Diabetes Center, Gentofte, Denmark
  3. 3Department of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark
  4. 4Regional Centre for Blood Transfusion and Clinical Immunology, Aalborg Hospital, Aalborg, Denmark
  5. 5Institute of Cardiovascular Research, Vrije Universiteit Medical Centre, Amsterdam, the Netherlands
  6. 6Faculty of Health Science, University of Aarhus, Aarhus, Denmark
  1. Address correspondence and reprint requests to Troels Krarup Hansen, MD, PhD, Immunoendocrine Research Unit, Medical Department M (Endocrinology & Diabetes), Aarhus University Hospital, Norrebrogade 42-44, DK-8000 Aarhus C, Denmark. E-mail: tkh{at}dadlnet.dk

Abstract

Complement activation and inflammation have been suggested in the pathogenesis of diabetic vascular lesions. We investigated serum mannose-binding lectin (MBL) levels and polymorphisms in the MBL gene in type 1 diabetic patients with and without diabetic nephropathy and associated macrovascular complications. Polymorphisms in the MBL gene and serum MBL levels were determined in 199 type 1 diabetic patients with overt nephropathy and 192 type 1 diabetic patients with persistent normoalbuminuria matched for age, sex, and duration of diabetes, as well as in 100 healthy control subjects. The frequencies of high- and low-expression MBL genotypes were similar in patients with type 1 diabetic and healthy control subjects. High MBL genotypes were significantly more frequent in diabetic patients with nephropathy than in the normoalbuminuric group, and the risk of having nephropathy given a high MBL genotype assessed by odds ratio (OR) was 1.52 (1.02–2.27, P = 0.04). Median serum MBL concentrations were significantly higher in patients with nephropathy than in patients with normoalbuminuria: 2,306 μg/l (interquartile range [IQR] 753–4,867 μg/l) vs. 1,491 μg/l (577–2,944 μg/l), P = 0.0003. In addition, even when comparing patients with identical genotypes, serum MBL levels were higher in the nephropathy group than in the normoalbuminuric group. Patients with a history of cardiovascular disease had significantly elevated MBL levels independent of nephropathy status (3,178 μg/l [IQR 636–5,231 μg/l] vs. 1,741 μg/l [656–3,149 μg/l], P = 0.02). The differences in MBL levels between patients with and without vascular complications were driven primarily by pronounced differences among carriers of high MBL genotypes (P < 0.0001). Our findings suggest that MBL may be involved in the pathogenesis of micro- and macrovascular complications in type 1 diabetes, and that determination of MBL status might be used to identify patients at increased risk of developing these complications.

Footnotes

  • S.T. is cofounder of NatImmune, Denmark, a biotech company producing recombinant MBL.

    • Accepted March 2, 2004.
    • Received December 18, 2003.
« Previous | Next Article »Table of Contents